Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT04094142 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

DRUG: Acalabrutinib

Sponsor

Seoul National University Hospital